| Hemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease. | |
| | |
MedLine Citation:
|
PMID: 14524034 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The study was designed to evaluate if there is any evidence of a hyperfibrinolytic bleeding-risk under systemic treatment with prostaglandin E1 (PGE1) of patients with peripheral arterial disease (PAD). PATIENTS AND METHODS: The in vivo effect of PGE1 on the fibrinolytic and hemostatic process was tested on 15 patients before and after treatment with Alprostadil for 21 days using D-dimers (DD), fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT), antithrombin (AT), ProC-Global, plasminogen, plasminogen activator inhibitor activity (PAI), alpha 2-antiplasmin, coagulation factor XII, basal and activated fibrinolytic capacity (fib. cap.). RESULTS: There was no significant difference in DD, fibrinogen, PT, PTT, AT, ProC-Global, plasminogen, PAI, alpha 2-antiplasmin, coagulation factor XII, basal and activated fibrinolytic capacity observed after the treatment. CONCLUSION: Summarizing this study there is no hyperfibrinolytic bleeding-risk after the systemic therapy with Alprostadil to be expected. |
| | |
Authors:
|
M Kuss; H Heidrich; E Koettgen |
Related Documents
:
|
22759664 - Alcohol and repeated deliberate self-harm. 23008394 - Anesthesia for endovascular treatment of acute ischemic stroke. 23252904 - Patient registries: useful tools for clinical research in myasthenia gravis. 23151224 - Not as transient: patients with transient ischaemic attack or minor stroke experience c... 22338974 - Patient satisfaction as a function of in-house versus contract staffing models in veter... 16824844 - The obesity paradox in non-st-segment elevation acute coronary syndromes: results from ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: VASA. Zeitschrift für Gefässkrankheiten Volume: 32 ISSN: 0301-1526 ISO Abbreviation: VASA Publication Date: 2003 Aug |
Date Detail:
|
Created Date: 2003-10-03 Completed Date: 2004-01-15 Revised Date: 2012-10-19 |
Medline Journal Info:
|
Nlm Unique ID: 0317051 Medline TA: Vasa Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 145-8 Citation Subset: IM |
Affiliation:
|
Institut für Laboratoriumsmedizin und Pathobiochemie, Medizinischen Fakultät Charité, Humboldt-Universität zu Berlin, Germany. marcella.kuss@web.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alprostadil / administration & dosage, adverse effects* Arterial Occlusive Diseases / blood, drug therapy* Blood Coagulation Factors / metabolism Blood Coagulation Tests Female Fibrinolysis / drug effects* Fibrinolytic Agents / adverse effects* Hemorrhage / blood, chemically induced* Hemostasis / drug effects* Humans Infusions, Intravenous Male Middle Aged Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Blood Coagulation Factors; 0/Fibrinolytic Agents; 745-65-3/Alprostadil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association between endothelial dysfunction and major cardiovascular events in peripheral arterial d...
Next Document: Surgical treatment of vasculo-Behçet's disease. A review of patients with concomitant multiple aneu...